Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.59 |
| ▸ | PLAU | P00749 | 3/20 | 0.57 |
| ▸ | MAPT | P10636 | 3/20 | 0.56 |
| ▸ | RAB9A | P51151 | 2/20 | 0.56 |
| ▸ | NPC1 | O15118 | 1/20 | 0.56 |
| ▸ | CA12 | O43570 | 3/20 | 0.56 |
| ▸ | CA1 | P00915 | 3/20 | 0.56 |
| ▸ | CA2 | P00918 | 3/20 | 0.56 |
| ▸ | CA9 | Q16790 | 3/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.53 |
| ▸ | ERN1 | O75460 | 1/20 | 0.51 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.50 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.50 |
| ▸ | FNTA | P49354 | 1/20 | 0.50 |
| ▸ | FNTB | P49356 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2875365 | 0.88 | CA12 (0.61) | PLAUMAPTRAB9ANPC1CA12 | |
| SCHEMBL29441704 | 0.88 | CA12 (0.61) | PLAUMAPTRAB9ANPC1CA12 | |
| SCHEMBL28189889 | 0.88 | EGFR (0.68) | EGFRPLAUCA12CA1CA2 | |
| Hydrochloric Acid SCHEMBL6233341 | 0.87 | CA12 (0.60) | PLAUMAPTRAB9ANPC1CA12 | |
| SCHEMBL27589486 | 0.86 | TSHR (0.64) | EGFRPLAUMAPTRAB9ACA12 | |
| SCHEMBL68931 | 0.84 | CA12 (0.69) | EGFRPLAUCA12CA1CA2 | |
| SCHEMBL1660752 | 0.83 | CA12 (0.68) | EGFRPLAUCA12CA1CA2 | |
| SCHEMBL1505173 | 0.83 | MECP2 (0.60) | MAPTRAB9ANPC1TP53SMN1; SMN2 | |
| SCHEMBL5943746 | 0.83 | LMNA (0.63) | MAPTRAB9ANPC1CA12CA1 | |
| SCHEMBL3200407 | 0.83 | GAA (0.51) | EGFRPLAUMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-103864750-A | Derivative of N-biphenyl dichloroacetamide as well as preparation method and applications thereof | UNIV TSINGHUA | 2014-06-18 | — | — | CN | claimed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2023-01-19 | — | — | US | disclosed |
| EP-3974426-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research and Technology Corporation (US) | 2022-03-30 | — | — | EP | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | INDIANA UNIVERSITY RESEARCH AND TECHNOLOGY CORPORATION (US) | 2021-03-16 | — | — | US | disclosed |
| WO-2020142809-A1 | METHOD OF TREATMENT AND DEVICE | MONASH UNIVERSITY (AU) | 2020-07-16 | — | — | WO | disclosed |
| EP-3607950-A2 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research & Technology Corporation (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3607950-A2 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | Indiana University Research & Technology Corporation (US) | 2020-02-12 | — | — | EP | disclosed |
| EP-3116316-B1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | UNIV INDIANA RES & TECH CORP (US) | 2019-07-10 | — | — | EP | disclosed |
| CN-1250776-A | Heterodicyclic compound derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| CN-1051548-C | Heterobicyclic derivatives, pharmaceutical compositions containing them, process for preparing them and their use | FUJISAWA PHARMACEUTICAL CO (JP) | 2000-04-19 | — | — | CN | disclosed |
| US-6040311-A | TREATING BONE DISORDERS FOR PREVENTING OSTEOPOROSIS OR INHIBITING BONE RESORPTION IN A MAMMAL; TREATING TUMOR GROWTH IN A MAMMAL | MERCK & CO., INC. (US) | 2000-03-21 | — | — | US | disclosed |
| WO-1999065877-A1 | THERAPEUTIC BIARYL DERIVATIVES | GLAXO GROUP LIMITED (GB) | 1999-12-23 | — | — | WO | disclosed |
| EP-0920867-A1 | Pyrido[2,3-a]pyrazine derivatives as PDE-IV and TNF inhibitors | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1999-06-09 | — | — | EP | disclosed |
| CN-1157617-A | Heterobicyclic derivatives | FUJISAWA PHARMACEUTICAL CO (JP) | 1997-08-20 | — | — | CN | disclosed |
| EP-0770079-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1997-05-02 | — | — | EP | disclosed |
| US-5599813-A | ANTIANGIOGENIC AGENTS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1997-02-04 | — | — | US | disclosed |
| WO-1996001825-A1 | HETEROBICYCLIC DERIVATIVES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1996-01-25 | — | — | WO | disclosed |
| EP-0618208-A1 | Thiazolopyrimidine derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1994-10-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019129-A1 | HEPATITIS B CORE PROTEIN ALLOSTERIC MODULATORS | HAVCR2, MAVS, FABP1 | EGFR 2893/4885PLAU 3943/4885MAPT 2680/4885 |
| US-10947224-B2 | Hepatitis B core protein allosteric modulators | HAVCR2, MAVS, FABP1 | EGFR 2893/4885PLAU 3943/4885MAPT 2680/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.